$2.05
0.49% yesterday
Nasdaq, Dec 02, 10:00 pm CET
ISIN
US0547544033
Symbol
AYTU

Aytu BioScience Inc Stock price

$2.05
-0.16 7.24% 1M
+0.27 15.17% 6M
+0.35 20.59% YTD
+0.42 25.77% 1Y
-2.45 54.44% 3Y
-172.61 98.83% 5Y
-3,014,397.95 100.00% 10Y
+1.73 540.63% 20Y
Nasdaq, Closing price Tue, Dec 02 2025
-0.01 0.49%
ISIN
US0547544033
Symbol
AYTU
Industry

Key metrics

Basic
Market capitalization
$20.9m
Enterprise Value
$15.4m
Net debt
positive
Cash
$32.6m
Shares outstanding
9.9m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
0.3 | 0.4
EV/Sales
0.2 | 0.3
EV/FCF
negative
P/B
0.9
Financial Health
Equity Ratio
15.3%
Return on Equity
-71.5%
ROCE
2.0%
ROIC
1.6%
Debt/Equity
1.2
Financials (TTM | estimate)
Revenue
$63.7m | $57.0m
EBITDA
$4.4m | $1.1m
EBIT
$1.2m | $-5.1m
Net Income
$-13.1m | $-17.0m
Free Cash Flow
$-4.5m
Growth (TTM | estimate)
Revenue
-15.6% | -14.2%
EBITDA
33.0% | -82.1%
EBIT
177.0% | -299.0%
Net Income
-109.1% | -25.2%
Free Cash Flow
-78.4%
Margin (TTM | estimate)
Gross
67.6%
EBITDA
6.9% | 2.0%
EBIT
1.9%
Net
-20.5% | -29.8%
Free Cash Flow
-7.0%
More
EPS
$-0.7
FCF per Share
$-0.4
Short interest
5.6%
Employees
102
Rev per Employee
$650.0k
Show more

Is Aytu BioScience Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,078 stocks worldwide.

Aytu BioScience Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Aytu BioScience Inc forecast:

8x Buy
89%
1x Hold
11%

Analyst Opinions

9 Analysts have issued a Aytu BioScience Inc forecast:

Buy
89%
Hold
11%

Financial data from Aytu BioScience Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
64 64
16% 16%
100%
- Direct Costs 21 21
13% 13%
32%
43 43
17% 17%
68%
- Selling and Administrative Expenses 38 38
18% 18%
59%
- Research and Development Expense 0.90 0.90
66% 66%
1%
4.39 4.39
33% 33%
7%
- Depreciation and Amortization 3.21 3.21
34% 34%
5%
EBIT (Operating Income) EBIT 1.18 1.18
177% 177%
2%
Net Profit -13 -13
109% 109%
-21%

In millions USD.

Don't miss a Thing! We will send you all news about Aytu BioScience Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Aytu BioScience Inc Stock News

Neutral
Accesswire
8 days ago
DENVER, CO / ACCESS Newswire / November 24, 2025 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, today announced that its management will participate at NobleCon21 - Noble Capital Markets' 21st Annual Emerging Growth Equity C...
Neutral
Seeking Alpha
19 days ago
Aytu BioPharma, Inc. ( AYTU ) Q1 2026 Earnings Call November 13, 2025 4:30 PM EST Company Participants Joshua Disbrow - CEO & Director Ryan J. Selhorn - CFO, Corporate Secretary & Treasurer Conference Call Participants Robert Blum - Lytham Partners, LLC Thomas Flaten - Lake Street Capital Markets, LLC, Research Division Nazibur Rahman - Maxim Group LLC, Research Division Edward Woo - Ascendiant...
Neutral
Accesswire
19 days ago
Total net revenue of $13.9 million Net income of $2.0 million, or $0.21 net income per share basic Adjusted EBITDA1 of $(0.6) million, which includes EXXUA launch investments $32.6 million cash balance at September 30, 2025 Company remains on track to launch EXXUA ™ (gepirone) extended-release tablets ("EXXUA " ) in the fourth calendar quarter of 2025 as a centerpiece of its commercial efforts ...
More Aytu BioScience Inc News

Company Profile

Aytu BioScience, Inc. is a specialty pharmaceutical company, which focuses on identifying, acquiring, and commercializing novel products. Its products include Natesto, Tuzistram, ZolpiMist and MiOXSYS. The company was founded on August 9, 2002 and is headquartered in Englewood, CO.

Head office United States
CEO Joshua Disbrow
Employees 102
Founded 2002
Website aytubio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today